A major international study has assessed key bacterial targets that could form the basis of a new maternal vaccine to protect ...

Neonatal sepsis remains a critical challenge in neonatal care, representing one of the leading causes of morbidity and mortality, particularly in low‐ and middle‐income settings. Characterised by a ...

Sepsis leads to life-threatening organ failure due to dysregulated host responses to infection and presents uniquely across age groups. Neonatal sepsis, affecting infants in their first 28 days, ...

A genetic signature in newborns can predict neonatal sepsis before symptoms even start to show, according to a new study. The study, led by University of British Columbia and Simon Fraser University ...

Researchers are calling for an urgent overhaul of diagnostic and treatment guidelines for infections in newborn babies, after a University of Sydney-led study revealed frontline treatments for sepsis ...

A new study into sepsis in neonatal babies has uncovered the secrets of the bacteria’s success in causing this life-threatening condition. Using genomic sequencing, they have found how certain strains ...

University of Maryland School of Medicine (UMSOM) researchers at the Center for Vaccine Development and Global Health (CVD) have been awarded $3.96 million to develop a maternal vaccine that prevents ...

The global coxsackievirus infections market, currently in its early stages, is driven by unmet medical needs, particularly in severe neonatal, cardiac, and neurological infections. Research is ...

Among the sample of 981,869 children, researchers found that the incidence rate of epilepsy was 1.6 and 0.9 per 1000 person-years for children with diagnosed sepsis and those without an infection, ...

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Glyprovac LLC US$467,000 to develop a maternal vaccine that targets Escherichia coli, a bacterial species ...